Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms

Hospital de Clinicas de Porto Alegre

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: placebo; Drug: memantine

Study type: Interventional

Funder types: Other

Identifiers

NCT00757978

05-406

FIPE-HCPA 05-406

Details and patient eligibility

About

Memantine as an add-on therapy to clozapine may improve schizophrenia negative symptoms and cognitive functioning.

Enrollment: 22 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Under clozapine with negative symptoms

Exclusion criteria

• Pregnancy
• Lactation

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

22 participants in 2 patient groups, including a placebo group

1

Placebo Comparator group

Description:

Clozapine plus placebo

Treatment:

Drug: placebo

2

Active Comparator group

Description:

Clozapine plus memantine

Treatment:

Drug: memantine